Immune Checkpoint Inhibitor-Related Autoimmune Pancreatitis-Risk Factors and Outcomes
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Jiang C, Tang W, Yang X, Li H
. Immune checkpoint inhibitor-related pancreatitis: What is known and what is not. Open Med (Wars). 2023; 18(1):20230713.
PMC: 10238808.
DOI: 10.1515/med-2023-0713.
View
2.
Hana C, Rehman T, Park K, Carracedo Uribe C, Aung P, Hunis B
. Pancreatic adverse events in patients treated with immune checkpoint inhibitors. JGH Open. 2023; 7(3):204-207.
PMC: 10037034.
DOI: 10.1002/jgh3.12875.
View
3.
Chennamadhavuni A, Abushahin L, Jin N, Presley C, Manne A
. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors. Front Immunol. 2022; 13:779691.
PMC: 9086893.
DOI: 10.3389/fimmu.2022.779691.
View
4.
Shimosegawa T, Chari S, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M
. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011; 40(3):352-8.
DOI: 10.1097/MPA.0b013e3182142fd2.
View
5.
Liu Y, Zhang H, Zhou L, Li W, Yang L, Li W
. Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management. Front Oncol. 2021; 11:627612.
PMC: 7959713.
DOI: 10.3389/fonc.2021.627612.
View